Send to

Choose Destination
J Neuroimmunol. 2008 Aug 30;200(1-2):1-10. doi: 10.1016/j.jneuroim.2008.05.017. Epub 2008 Jul 22.

Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine.

Author information

Johnnie B. Byrd, Sr., Alzheimer's Center and Research Institute, 4001 East Fletcher Avenue, Tampa, FL 33613, United States.


Vaccines using bone marrow-derived dendritic cells (DCs) sensitized to Abeta 1-42 peptide and other mutant peptides were tested on BALB/c and APP(SW) transgenic mice. Wild type Abeta 1-42-sensitized DC vaccine (DCSV) produced no response, but all peptides with a T-cell epitope mutation induced antibody responses without inflammation. DCSV with Abeta 1-25 peptide with mutated T-cell epitope failed to induce antibody response, while DCSV with Abeta 1-35 with mutated T-cell epitope produced a strong antibody response. The entire T-cell epitope is required in a DC vaccine to induce antibody response. DCSV with Abeta peptide carrying the entire mutant T-cell epitope may be an appropriate vaccine against AD.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center